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Bone tissue constitutes a fertile ‘soil’ for metastatic tumours, notably breast cancer. High concentrations of growth factors in bone
matrix favour cancer cell proliferation and survival, and a vicious cycle settles between bone matrix, osteoclasts and cancer cells.
Classically, bisphosphonates interrupt this vicious cycle by inhibiting osteoclast-mediated bone resorption. We and others recently
reported that bisphosphonates can also induce human breast cancer cell death in vitro, which could contribute to their beneficial
clinical effects. We hypothesised that bisphosphonates could inhibit the favourable effects of ‘bone–derived’ growth factors, and
indeed found that bisphosphonates reduced or abolished the stimulatory effects of growth factors (IGFs, FGF-2) on MCF-7 and
T47D cell proliferation and inhibited their protective effects on apoptotic cell death in vitro under serum-free conditions. This could
happen through an interaction with growth factors’ intracellular phosphorylation transduction pathways, such as ERK1/2-MAPK. In
conclusion, we report that bisphosphonates antagonised the stimulatory effects of growth factors on human breast cancer cell
survival and reduced their protective effects against apoptotic cell death. Bisphosphonates and growth factors thus appear to be
concurrent compounds for tumour cell growth and survival in bone tissue. This could represent a new mechanism of action of
bisphosphonates in their protective effects against breast cancer-induced osteolysis.
British Journal of Cancer (2003) 89, 178–184. doi:10.1038/sj.bjc.6601009 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: bisphosphonates; bone metastases; growth factor; breast cancer; apoptosis
                                             
Breast and prostate cancers most often metastasise to bone
(Yoneda et al, 2000). A ‘seed and soil’ hypothesis (Paget, 1889) can
explain this phenomenon. The bone extracellular matrix is rich in
growth factors (Hauschka et al, 1986), which are released during
the continuous remodelling process and favour cancer cell
proliferation and survival (Barnes, 1988; Geier et al, 1992; Quinn
et al, 1996). On the other hand, breast cancer cells are able to
stimulate bone resorption by increasing osteoclast recruitment and
proliferation as well as the activity of mature osteoclasts (Mundy,
1991; Taube et al, 1994; Yoneda et al, 2000). Bone microenviron-
ment will then be even more enriched in bone-derived growth
factors that enhance proliferation and survival of cancer cells. This
sets up a vicious cycle between cancer cells, osteoclasts and bone
matrix.
Bone metastases are responsible for considerable misery in
cancer patients. Bisphosphonates reduce the skeletal morbidity
rate in breast cancer patients with bone metastases by up to
40–50% (Paterson et al, 1993; Body et al, 1998; Hortobagyi et al,
1998; Theriault et al, 1999; Body, 2001) and they can decrease the
number and the extent of bone metastases in animal models of
tumour-induced osteolysis (Hughes et al, 1995; Hiraga et al, 2001)
as well as in patients treated in the adjuvant setting (Coleman,
2002; Powles et al, 2002).
Bisphosphonates are synthetic analogues of pyrophosphate in
which the oxygen bridge is replaced by a carbon atom that allows
the attachment of various side chains. Bisphosphonates are very
stable compounds that exhibit a high affinity for calcified matrices
such as hydroxyapatite in bone (Lin, 1996), and are successfully
used as powerful inhibitors of increased bone resorption in several
bone diseases (Fleisch, 1997a, b). They act by decreasing
the recruitment, proliferation and differentiation of preosteoclasts
(Lowik et al, 1988; Hughes et al, 1989; Nishikawa et al, 1996), their
adhesion to the mineralised matrix and, most importantly,
the resorptive activity of mature osteoclasts (Sato et al, 1991;
Selander et al, 1994; Azuma et al, 1995; Murakami et al, 1995).
They also shorten osteoclast lifespan by induction of programmed
cell death (apoptosis) (Hughes et al, 1995). In addition, the
inhibitory activity of bisphosphonates on bone resorption may
be indirectly mediated by other cells such as cells of the
osteoblastic lineage or the macrophage family (Sahni et al, 1993;
Nishikawa et al, 1996; Vitte et al, 1996; Siwek et al, 1997; Fromigue
and Body, 2002). On the other hand, we and others (Fromigue
et al, 2000; Senaratne et al, 2000; Jagdev et al, 2001b) previously
showed that bisphosphonates can induce human breast cancer cell
death in vitro (apoptosis and/or necrosis), which could contribute
to their beneficial clinical effects. Thus, bisphosphonates exhibit
beneficial effects on bone integrity by reducing bone resorption
induced by osteoclasts and maybe also by direct ‘antitumoral’
effects.
In cancer patients treated with bisphosphonates, metastatic
breast cancer cells in bone are thus exposed to both bispho-
sphonates, which can induce their death, and to growth factors,
which, in contrast, may stimulate their growth and survival. We
investigated the effects of combinations of bisphosphonates and
several ‘bone-derived’ growth factors on breast cancer cell survival
to examine if bisphosphonates could also inhibit the stimulatory Received 7 January 2003; revised 3 April 2003; accepted 13 April 2003
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sand protective effects of growth factors on breast cancer cells. Our
data point to a possibly new mode of action of bisphosphonates in
the process of breast cancer-induced osteolysis.
MATERIALS AND METHODS
Materials
Media, supplements and plastic culture materials were obtained
from Life Technologies SA (Merelbeke, Belgium). Recombinant
human insulin-like growth factor types I and II (IGF-I and -II),
basic fibroblast growth factor (FGF-2) and epidermal growth factor
(EGF) were purchased from R&D Systems (Abingdon, Oxon, UK).
Pamidronate (3-amino-1-hydroxypropylidene bisphosphonic acid)
and zoledronic acid (2-imidazol-1-yl-1-hydroxyethylidene-1,1 bi-
sphosphonic acid) were provided by Novartis (Basel, Switzerland).
Zoledronic acid evidently becomes zoledronate in culture condi-
tions, explaining why we used this last term thoughout the Results.
Clodronate (dichloromethylene bisphosphonic acid) and ibandro-
nate (1-hydroxy-3-methylpentylamino-propylidene bisphosphonic
acid) were provided by Hoffmann-LaRoche (Basel, Switzerland).
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bro-
mide) reagent and rabbit anti-b-actin antibody were obtained from
Sigma-Aldrich SA (Bornem, Belgium). Ac-IETD-AMC and
Ac-DEVD-AMC were obtained from Pharmingen (Erembodegem-
Aalst, Belgium). The 7-amino-4-methylcoumarin was from
Bachem Feinchemikalien AG (Bubendorf, Switzerland). The mouse
bax and bcl-2 antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The phosphospecific
antibodies anti-ERK1/2 MAPK, -p38 MAPK and -JNK were
purchased from New England Biolabs Inc. (Beverly, MA, USA),
and secondary antibodies conjugated with horseradish peroxidase
were from Dako (Denmark).
MTT test
Subconfluent cells were washed twice in PBS before addition of
phenol red-free and serum-free medium containing or not the
indicated agents (bisphosphonates or growth factors). We
previously tested and compared several techniques (MTT test, cell
counting, total DNA content and BrdU incorporation) to
investigate breast cancer cell survival under serum-free conditions.
In this study, we used the MTT test as previously described, and all
significant effects were validated by cell counting. We used six
replicates for each condition and experiments were repeated at
least three times. Results are means7s.e.m. of treated/control
ratios.
Caspase activity
After 3, 8, 15, 24 and 48h of incubation under serum-free
conditions, cells were trypsinised and processed as previously
described (Fromigue et al, 2000). Briefly, caspases activities
were assessed by the cleavage of synthetic fluorogenic substrates
containing the amino-acid sequences IETD: Ile-Glu-Thr-Asp
(caspase-8), or DEVD: Asp-Glu-Val-Asp (effector caspase -3,
-6 and -7) combined to a fluorophore (AMC). MCF-7 cell line
is known to be devoid of a caspase-3 activity (Janicke et al,
1998), which results in the determination of caspase-6 and -7
activities by the DEVD-AMC substrate. Results, obtained as nmol
AMCh
 110
 6 cells, are expressed as treated over control ratios.
Western blotting
Attached cells, collected by trypsinisation, were pooled with the
floating cells, lysed in 10mM Tris-HCl pH 7.4, 20mM NaCl, 1%
NP40, 0.5% deoxycholate Na and 0.1mM PMSF for 30min on ice
and centrifuged. Proteins were separated on 12% SDS–PAGE and
electrotransferred onto PVDF membranes. Filters were blocked in
10mM Tris-HCl pH 7.4, 150mM NaCl, 1mM EDTA, 0.1% Tween-20,
3% BSA and 0.5% gelatin for 3h, then incubated overnight with
primary antibody (1:500 for b-actin, 1:1000 for bax or bcl-2).
Filters were washed twice before incubation for 1h with the
secondary antibody conjugated with horseradish peroxidase
(1:2500). After three final washes, filters were exposed following
the enhanced chemiluminescence detection reagent (Amersham,
Les Ulis, France) to an autoradiographic film (Kodak, Vilvoorde,
Belgium). For detection of the phosphorylation state of p38-,
ERK1/2-MAPKs and JNK, subconfluent cells were washed twice in
PBS before incubation with phenol red-free and serum-free
medium containing bisphosphonates and/or growth factors. After
2, 5, 10 or 30min, culture media were removed and flasks
immersed in dry ice-cold methanol. Cell layers were then lysed as
described above. Phospho-specific primary antibodies were used
at the dilution 1:2000.
Statistical analysis
Statistical analysis was performed using classical statistical tests
(package Super ANOVA; Macintosh, Abacus concepts Inc.,
Berkeley, CA, USA) with a statistical significance level at least
o0.05 (Fisher’s PLSD).
RESULTS
Dose–response effects of growth factors on breast
cancer cells
Cell survival was assessed by the MTT test and all significant
effects were validated by cell counting (see Materials and methods;
data not shown). We checked the effects of four different growth
factors on the viability under serum-free conditions of two
classical breast cancer cell lines, namely MCF-7 and T47D.
Exposure to IGF-I (0.1–100ngml
 1) or IGF-II (1–1000ngml
 1)
for 24h increased cell survival in a dose-dependent manner. IGF-I
induced a bell-shaped growth curve with a peak at 10ngml
 1
(up to þ26%, Po0.005; Figure 1A). Lower concentrations
(1–5ng ml
 1) already significantly increased cell viability and
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Figure 1 Modulation of breast cancer cell survival by growth factors.
Breast cancer cells (J, MCF-7 and ’, T47D) were incubated for 24h
under serum-free conditions, without or with increasing concentrations of
IGF-I, IGF-II, FGF-2 or EGF. Cell viability was evaluated using the MTT test
and expressed as treated over control ratios (means7s.e.m., n¼15–20).
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sconcentrations above 50ng ml
 1 had lower stimulatory effects.
Doses 10–50-fold higher were required for IGF-II to detect
stimulatory effects comparable to IGF-I. In contrast to IGF-I,
IGF-II did not exhibit a biphasic pattern, but dose-dependently
increased MCF-7 cell survival, at least up to 1000ngml
 1 (þ50%,
Po0.05; Figure 1B). IGF-II also dose-dependently improved T47D
cell survival and the stimulatory effects persisted for concentra-
tions above 100ngml
 1, then plateaud (þ15%, Po0.05;
Figure 1B). These data confirm that IGFs can increase MCF-7
and T47D cell survival and indicate that IGF-II was about 10-fold
less potent than IGF-I in our model. FGF-2 dose-dependently
increased MCF-7 and T47D cells survival (up to þ36%, Po0.05;
Figure 1C). Very low concentrations of 0.05ngml
 1 increased cell
viability by about 10% (Po0.02). The maximal stimulatory effect
was observed for concentrations of 5–10ngml
 1 for both cell lines
(þ30%, Po0.001). Higher concentrations did not improve T47D
nor MCF-7 cell viability. Lastly, EGF (1–100ngml
 1) did not exert
any significant effect on MCF-7 or T47D cell survival (Figure 1D).
We thus did not further investigate the possible modulatory effects
of bisphosphonates on the effects of this particular growth factor.
Bisphosphonates inhibit growth factors’ proliferative
effects
We then investigated the effects of bisphosphonates in combina-
tion with growth factors on breast cancer cell viability under
serum-free conditions. Bisphosphonates were all tested at the
concentration of 10
 6 M and inhibited cell viability by up to 27% in
MCF-7 cells and by up to 36% in T47D cells (see Fromigue ´ et al,
2000). IGF-I, IGF-II and FGF-2 were used at concentrations
exhibiting optimal or suboptimal stimulatory effects, that is,
10ngml
 1 for IGF-I, 100ngml
 1 for IGF-II and 5ngml
 1 for FGF-
2 (see Figure 1). In MCF-7 cells, the most impressive effects of
bisphosphonates were observed with FGF-2 (Figure 2, upper panel)
since all four bisphosphonates almost completely abolished the
FGF-2 stimulatory effects (86–99% inhibition). The effects of IGFs
were less inhibited by bisphosphonates (reduction of 20–68% of
their proliferative effect). For the T47D cell line, we found a quite
different pattern since FGF-2-treated cells were not affected by
bisphosphonates (Figure 2, lower panel), whereas IGF-I effects
were completely abolished by all four tested bisphosphonates.
Clodronate and ibandronate also fully inhibited IGF-II stimulatory
effects on T47D cell survival, whereas pamidronate and zoledro-
nate partly reduced (by 43 and 72%, respectively) IGF-II effects
(Figure 2, lower panel). These data show that bisphosphonates can
completely or partly inhibit growth factors’ stimulatory effects on
breast cancer cell survival. No marked differences could be noticed
between the four bisphosphonates except that pamidronate was
often the least potent compound.
Differential effects of bisphosphonates and growth factors
on apoptosis
We previously reported that bisphosphonates reduce breast cancer
cell survival by inducing both programmed cell death (apoptosis)
and direct necrosis in the MCF-7 cell line, whereas necrosis is the
main mechanism involved in the reduction of T47D cell survival
(Fromigue et al, 2000). The bisphosphonate-induced apoptotic
process in MCF-7 cells is characterised by a time-dependent
activation of effector caspases. We investigated the modulation of
the activity of initiator (caspase-8) and effector caspases (caspase-6
and -7) in MCF-7 cells incubated in the presence of bispho-
sphonates and growth factors. No modulation of caspase-8 activity
was detected in bisphosphonates and/or growth factors treated
cells (data not shown). We found that neither IGF-I nor IGF-II nor
FGF-2 significantly modified the basal levels of effector caspases
activity in MCF-7 cells at any time (from 3 to 48h; data not
shown). However, when a bisphosphonate and a growth factor
were simultaneously added in MCF-7 cells culture medium, we
found a marked reduction in bisphosphonate-induced stimulation
of effector caspases activity (Figure 3). These data suggest that
MCF-7 cells
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Figure 2 Bisphosphonates reduce growth factors’ stimulatory effects on
human breast cancer cell survival. MCF-7 cells (upper panel) and T47D cells
(lower panel) were incubated for 24h under serum-free conditions, in the
presence of 10
 6 M pamidronate (P), clodronate (C), ibandronate (I) or
zoledronate (Z), and of IGF-I (10ngml
 1), IGF-II (100ngml
 1) or FGF-2
(5ngml
 1). Cell viability was evaluated by the MTT test and expressed as
the percentage of growth factors’ effects alone (means7s.e.m., n¼18–
20). *:Po0.05 vs growth factor alone.
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Figure 3 Modulations of effector caspases activity in MCF-7 cells.
Subconfluent MCF-7 cells were incubated in the presence of 10
 6 M
bisphosphonates and IGF-I (10ngml
 1), IGF-II (100ngml
 1) or FGF-2
(5ngml
 1) for up to 48h. Effector caspases (caspase -6, -7) activity was
determined at different time points using a synthetic fluorogenic substrate
(DEVD-AMC, see Materials and methods). Results are shown as treated
over control ratios (n¼3).
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sgrowth factors could attenuate bisphosphonate-induced MCF-7
cells apoptosis by lowering the caspases induction.
Other intracellular effectors are involved in the induction of
apoptosis. The ratio between proapoptotic proteins (such as bax)
and antiapoptotic proteins (such as bcl-2) determines whether a
cell will undergo apoptosis or will be protected from it (Adams and
Cory, 1998). We investigated the effects of growth factors and of
bisphosphonates, alone or in combination, on bax and bcl-2
protein levels in MCF-7 cells, and found that all four bispho-
sphonates increased the bax/bcl-2 ratio (Figure 4A) whereas IGF-I
and FGF-2 significantly decreased the same ratio (Figure 4B). The
effects of IGF-II were not significant. When bisphosphonates were
combined with IGF-I or FGF-2, we observed a reduction in the
antiapoptotic effect of growth factors on MCF-7 cells (Figure 4C).
IGF-I protective effects were reduced by 50–100% (Po0.05) by
bisphosphonates and the ones of FGF-2 by 19–75% (Po0.05).
These data indicate that bisphosphonates could reduce the
protective effects of growth factors on MCF-7 cell survival by
significantly reducing their antiapoptotic potential.
Bisphosphonates and FGF-2 modulate cell survival
signalling pathways
Cell survival is classically upregulated by growth factors such
as IGFs or FGF-2 via intracellular signalling pathways involving
mitogen-activated protein kinases (MAPK) or stress-activated
protein kinases (SAPK). We investigated by Western blotting
the effects of bisphosphonates and/or growth factors on phos-
phorylation states of these kinases in MCF-7 breast cancer cells.
No modulatory effects on p38-MAPK or JNK phosphorylation
levels could be detected under bisphosphonates or/and growth
factors treatments (data not shown). By contrast, IGFs weakly
stimulated ERK1/2-MAPK phosphorylation (by about 10%
after 5–10min, data not shown), whereas FGF-2 induced a marked
increase in ERK1/2-MAPK phosphorylation status (by a maximum
of 2.3-fold compared to untreated cells after 10min; Figure 5).
In contrast, all four bisphosphonates induced a slight decrease
in phospho-ERK1/2 rates (by 7–16%; Figure 5). When FGF-2
and bisphosphonates were combined, the effects of FGF-2
were markedly or completely inhibited (Po0.05). These
initial data suggest that bisphosphonates and FGF-2 can modulate
in opposite directions the phosphorylation status of common
signalling pathways such as MAPK, which is involved in
the balance between induction of and protection against cell
death.
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Figure 4 Modulations of the bax/bcl-2 ratio in MCF-7 cells. Subconfluent
MCF-7 cells were incubated for 24h, under serum-free conditions, in the
absence or presence of 10
 6 M pamidronate (P), clodronate (C),
ibandronate (I), zoledronate (Z), 10ngml
 1 IGF-I or 5ngml
 1 FGF-2.
Bax and bcl-2 expression levels were determined by Western blot and
corrected for b-actin levels. Results are expressed as means7s.e.m. of the
bax/bcl-2 ratio (n¼4–10). *:Po0.05 vs control. (A) Blots and derived
ratios under bisphosphonates treatment. (B) Blots and derived ratios under
growth factors treatments. (C) Relative intensity of signals under
combinations of growth factors (IGF-I or FGF-2) and bisphosphonates. a:
Po0.05 vs control; b: Po0.05 vs growth factor alone.
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Figure 5 Modulation of the ERK-MAPK phosphorylation status in MCF-7
cells. (A) MCF-7 cells were incubated for 10min with bisphosphonates
(10
 6 M) and/or FGF-2 (5ngml
 1) in phenol red-free and serum-free
medium. Cell lysates were analysed by Western blot for phospho-p42/p44
and total p42 expression as described in Materials and methods section.
(B) Relative intensity of signals, after scan and software analyses
(ImageQuant). Results are expressed as percentages of controls.
PAM¼pamidronate; CLOD¼clodronate; IBAN¼ibandronate and
ZOLE¼zoledronate.
Bisphosphonates interact with bone growth factors
O Fromigue et al
181
British Journal of Cancer (2003) 89(1), 178–184 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sDISCUSSION
The high concentrations of growth factors in bone matrix provide
a fertile ‘soil’ for metastatic breast cancer cells (hypothesis
proposed by Paget, 1889). When tumour cells arrive in bone,
a vicious cycle arises since they stimulate osteoclast-induced
bone resorption, enhancing the supply of bone-derived growth
factors in the bone microenvironment. This may explain why
bone tissue is the most frequent organ in which breast cancers
develop distant metastases (Boyce et al, 1999; Yoneda et al, 2000).
IGFs are the most abundant growth factors stored in bone matrix
(Mohan and Baylink, 1996) and, more importantly, are potent
survival factors for a wide range of tumour cells, notably breast
cancer cells (Dunn et al, 1997), by exerting both mitogenic
and antiapoptotic effects (Osborne et al, 1990; Baserga et al, 1994).
The role of IGF-I as a survival factor for cells in culture was
first demonstrated in IL-3-dependent haemopoietic cells (Rodri-
guez-Tarduchy et al, 1992). Removal of IL-3 results in
cell apoptosis, which can be blocked by adding IGF-I to
cell cultures. In the same way, FGF-2 can stimulate cancer cell
proliferation and prevent cell death (Miyake et al, 1997). There is
thus substantial evidence to indicate that IGFs and FGF-2
are critical survival factors for cancer cells, and that metastases
development is indeed dependent on such survival signals. We
first examined the modulation of breast cancer cell survival in
the presence of IGF-I, IGF-II, FGF-2 or EGF, and we confirmed
that, except for EGF, these growth factors promoted MCF-7
and T47D cell survival in vitro under serum-free conditions.
In agreement with other authors’ data (McCarthy et al, 1989),
we observed that IGF-II was about 10-fold less potent than
IGF-I to increase breast cancer cell survival under serum-free
conditions.
Bisphosphonates are synthetic compounds that preferentially
accumulate in bone (Sato et al, 1991) by their strong affinity for
calcified matrix. They are powerful inhibitors of osteoclast-
mediated bone resorption (Fleisch, 1991, 1997a; Russell and
Rogers, 1999), and they significantly reduce skeletal morbidity in
advanced breast cancer patients (Body, 2000). Bisphosphonates
can also decrease the number of bone metastases (Hall and Stoica,
1994; Powles et al, 2002). Moreover, we and others recently
demonstrated that, in vitro, bisphosphonates irreversibly reduce
breast cancer cell viability by inducing cell death, either by
apoptosis or by direct cell necrosis (Fromigue et al, 2000;
Senaratne et al, 2000; Jagdev et al, 2001a). The exact mechanism
of action of bisphosphonates is unknown. We checked the
hypothesis of a cation chelation by testing increasing concentra-
tions of EDTA on MCF-7 cell viability and apoptosis. No
significant effect was detected even at the highest concentration
(10
 4 M; data not shown). Recent data go along the same line
(Jagdev et al, 2001a) and led us to discard the possibility that the
observed effects are due to simple cation chelation by the
bisphosphonates.
It is difficult to know or to evaluate the concentrations of
bisphosphonates that are reached in the bone microenvironment
in vivo. Studies in rats revealed that concentrations as high as
10
 4 M or 10
 3 M can be reached in resorption lacunae (Sato et al,
1991). The concentrations we chose (10
 6 M) could thus be easily
reached in the skeleton, and it did not induce strong toxicity in
vitro as it can be observed for concentrations of 10
 4 or 10
 3 M
(Fromigue et al, 2000). We showed here that this relatively low
concentration was able to block growth factors’ effects, and to
inhibit the ‘protective’ effect of growth factors on breast cancer cell
survival. The effects of bisphosphonates that we observed were
thus obtained with relatively low concentrations of bispho-
sphonates, in contrast to earlier works that reported the
requirement for higher concentrations, between 20 and 1000mM,
to exhibit antitumour effects (Senaratne et al, 2000; Lee et al, 2001;
Jagdev et al, 2001a).
Our hypothesis is thus that in bisphosphonate-treated patients,
metastatic breast cancer cells in bone are influenced by various
growth factors, which may promote cell survival and/or cell
growth, but they can also be in contact with bisphosphonates that
might induce their death. A ‘competition’ between these two
opposite effects could thus modulate breast cancer cell prolifera-
tion and death. Very few data are available on the potential
interactions between bisphosphonates and growth factors, but it
was recently reported that administration of bisphosphonates to
patients with bone metastases significantly decreases serum FGF-2
concentrations (Zimering, 2002). It has also been shown that
pamidronate inhibits the effects of GH and decreases IGF-I levels
in rats (Kapitola et al, 2000), or inhibits the effects of G-CSF on
bone cells (Suzuki et al, 1999). Our first experiments showed that
when both growth factors and bisphosphonates were simulta-
neously added to cell cultures, the stimulatory effects of growth
factors on cell survival were markedly decreased (for IGFs) or even
abolished (for FGF-2). The increased cell survival observed in
IGFs-treated cells can be explained by an inhibition of apoptosis,
confirmed for example by a decrease in the bax/bcl-2 ratio (Jung
et al, 1996; Dunn et al, 1997; Xu et al, 1997). Bisphosphonates
could counterbalance these protective effects of bone-derived
growth factors on human breast cancer cell survival. On the other
hand, we confirmed a time-dependent increase in caspases activity
under bisphosphonate treatment, as previously described (Fromi-
gue et al, 2000). This stimulation was almost completely abolished
when MCF-7 cells were incubated with both growth factors and
bisphosphonates.
In in vivo conditions, due to bisphosphonate-induced decrease
in bone turnover, the release of bone-derived growth factors
should be diminished, resulting in a less favourable microenvir-
onment for cancer cells growth. This would come in addition to the
inhibition by bisphosphonates of the protective effects of growth
factors on cancer cells that we report here. Bisphosphonates and
growth factors thus appear to be concurrent compounds for
tumour cell survival in bone tissue. There might be a simple
balance between opposite effects or a real antagonism between
these two classes of compounds. We thus tried in the last part of
this report to start to characterise such possible interactions. The
exact intracellular mechanisms of action of bisphosphonates are
still to be further delineated and our preliminary data could point
to a new molecular mode of action of bisphosphonates.
In this study, we tested four structurally different bispho-
sphonates, known to exhibit variable potencies in bone resorption
inhibition. Indeed, clodronate and pamidronate are bisphospho-
nates of first/second generations. In contrast, ibandronate and
zoledronic acid are last generation bisphosphonates that represent
the two most potent compounds (Hiraga et al, 2001; Jagdev et al,
2001a; Rosen et al, 2001; Body, 2003; Lipton, 2003). Despite their
marked differences in potency to inhibit bone resorption in vitro
or in vivo, we did not observe major differences between the
potency of these four compounds in our in vitro experiments. It is
now accepted that nitrogen-containing bisphosphonates can
inhibit osteoclast activity through the mevalonate pathway (Luck-
man et al, 1998; Benford et al, 1999; van Beek et al, 1999; Coxon
et al, 2000). In our model, it appears likely that modulations of the
mevalonate pathway by nitrogen-containing bisphosphonates
cannot entirely explain the effects we observed on human breast
cancer cells since all four tested compounds reduced bone growth
factors’ effects on cell survival at about the same degree. Indeed,
pamidronate, ibandronate and zoledronate are nitrogen-contain-
ing bisphosphonates, which interfere with the mevalonate path-
way, whereas clodronate does not and is actually metabolised into
a toxic ATP analogue (Frith et al, 1997). A common characteristic
to these four structurally different compounds is evidently the
presence of two phosphate groups, which could suggest that
bisphosphonates could interact with intracellular phosphorylation
signalling pathways (including kinases, phosphorylation reactions
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reported modulations of protein–tyrosine phosphatase activity by
alendronate in osteoclasts (Schmidt et al, 1996) and of the MAPK
pathway in osteoblasts by six different bisphosphonates (Plotkin
et al, 1999). It is also well known that growth factors modulate cell
metabolism through interactions with specific kinase receptors
and intracellular signal transduction through MAPK or PI-3K
pathways (Dufourny et al, 1997; Imai and Clemmons, 1999). We
evaluated the phosphorylation state of JNK, ERK1/2 and p38
MAPK after incubation with bisphosphonates and/or growth
factors. No modification in JNK and p38 phosphorylation levels
was detectable by Western blot, but the ERK1/2 pathway was
clearly affected, suggesting a modulation of cell survival and not a
response to stress (Xia et al, 1995). As expected, FGF-2 induced a
marked increase in ERK1/2 phosphorylation status but, interest-
ingly, bisphosphonates decreased ERK1/2 phosphorylation and
attenuated FGF-2 effects. Further experiments should evidently be
performed, but these preliminary data suggest another possible
mechanism of intracellular action of bisphosphonates.
In conclusion, in addition to the previously demonstrated direct
‘antitumour’ effects of bisphosphonates, the present report
indicates that bisphosphonates might antagonise the stimulatory
effects of growth factors on the proliferation of breast cancer cells
and counterbalance their protective effects on breast cancer cell
death. Changes in intracellular phosphorylation transduction
pathways could partly explain our observations. Maybe impor-
tantly from a clinical point of view, these effects could contribute
to the beneficial activity of bisphosphonates and appear to indicate
that the mechanism of inhibition of tumour-induced osteolysis by
bisphosphonates is much more complex than a ‘simple’ anti-
osteoclast activity. Our findings may thus represent a novel
mechanism of action of bisphosphonates in the process of
inhibition of tumour-induced osteolysis.
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